YOU may be keen to shed pounds from your waistline with fat jabs, but forking out the monthly bill is less appealing – ...

The arrival of Wegovy two years ago caused turmoil in health services around the world ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...